CareDx, Inc.
CDNAHealthcareNASDAQDiagnostics & Research · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, CareDx, Inc. (CDNA) is listed under Diagnostics & Research. The company carries a $2.05B market cap, placing it firmly in the mid-cap category. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Market Cap
$2.05B
Beta
2.43
P/E (TTM)
—
P/E (Fwd)
35.04
EPS (TTM)
$-0.16
EPS (Fwd)
$1.13
ROE
-2.4%
ROA
-1.8%
Cash
$187.2M
Total Debt
$24.5M
Free CF
$70.1M
52W Change
233.4%
Annual Financials
Cash vs Debt
CareDx, Inc. holds $187.2M in cash against $24.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $70.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -2.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $321.8M to $379.8M.
A beta of 2.43 means CDNA is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, CDNA has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence CareDx, Inc.'s trajectory.